"Prototype Drug Uses Novel Mechanism To Treat Lung Cancers"
Cells are constantly turning proteins on and off via molecular switches-phosphate molecules-that have become common drug targets. Researchers collaborated to screen a series of drug-like molecules for their ability to reactivate PP2A in lung cancer cells and prevent lung cancer tumors in mice. The prototype drug molecules were created from FDA-approved medications by Michael Ohlmeyer, PhD, an associate professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai.
- Michael Ohlmeyer, PhD, Associate Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai
Learn more
The Mount Sinai Hospital Ranked Among Top in the Nation by U.S. News & World Report®
Jul 29, 2025 View All Press Releases
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases
Mount Sinai’s Cancer Science in the Spotlight at 2025 ASCO
May 29, 2025 View All Press Releases
Mount Sinai Study Advances Understanding of Personalized Vaccines for Bladder Cancer
May 12, 2025 View All Press Releases
Mount Sinai Researchers Discover How Melanoma May Spread to the Brain
Apr 30, 2025 View All Press Releases
Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Apr 24, 2025 View All Press Releases